European shares trading on US exchanges as American depositary receipts (ADRs) ticked higher late Friday morning, with the S&P Europe Select ADR Index climbing 0.42% to 1,881.24. The move was led by gains in BioNTech and Nokia, two of the most actively traded European ADRs.
ADRs are a way for US investors to buy shares of foreign companies without dealing with overseas exchanges or currency conversions. Each ADR represents a certain number of shares in the underlying company, and they trade on US exchanges just like domestic stocks. The S&P Europe Select ADR Index tracks a basket of these instruments, giving a snapshot of how European equities are performing in the US market.
What's driving the gains?
BioNTech, the German biotech company best known for its COVID-19 vaccine partnership with Pfizer, was among the top performers. While the company's vaccine revenue has declined sharply since the pandemic peak, it has been investing heavily in oncology and other therapeutic areas. Investors may be reacting to recent clinical trial updates or broader sector momentum, though the brief does not specify a particular catalyst.
Nokia, the Finnish telecommunications equipment maker, also contributed to the index's rise. Nokia has been a focus for investors due to its role in 5G infrastructure and recent contract wins, as well as its ongoing patent licensing disputes. The stock has been volatile, but Friday's uptick suggests some positive sentiment.
The broader context is also important. European markets have been navigating a mixed earnings season, with energy companies benefiting from higher oil prices while other sectors face headwinds. As Europe's Q3 earnings forecast climbs to 21% growth, much of that is skewed by energy names, so the ADR index's move reflects a broader, if modest, appetite for European equities.
What it means for investors
For everyday investors, a rise in European ADRs can be a signal that international diversification is paying off. When US markets are flat or volatile, European stocks can offer a different set of drivers, such as currency movements, local economic data, and company-specific news. However, ADRs also carry currency risk: if the euro weakens against the dollar, that can eat into returns even if the underlying stock rises.
Friday's move is relatively small, so it's not a major market event. But it does highlight that European equities are participating in the global rally, albeit at a slower pace than some other regions. For example, Asian ADRs edged up Friday but still ended the week lower, showing that regional performance can diverge.
Investors with exposure to European ADRs should keep an eye on the upcoming earnings season. As Europe's Q3 earnings forecast climbs to 21% growth, the energy sector is a big driver, but other sectors like healthcare and technology could surprise. BioNTech and Nokia are both in sectors that are closely watched.
Looking ahead
The ADR index's rise comes amid a broader backdrop of mixed global cues. US futures have been edging higher as SpaceX spectrum deal lifts sentiment, and oil prices have been cooling, which can help consumer-facing stocks. For European ADRs, the key factors to watch are the euro's strength, corporate earnings, and any central bank signals from the European Central Bank.
While Friday's gain is modest, it's a reminder that European stocks can be a useful diversifier. For those considering adding international exposure, ADRs offer a convenient way to do so without opening a foreign brokerage account. However, as with any investment, it's important to understand the specific risks, including currency fluctuations and geopolitical events.
In summary, the S&P Europe Select ADR Index's 0.42% rise, led by BioNTech and Nokia, is a small but positive sign for European equities in the US market. For investors, it underscores the value of keeping an eye on international markets as part of a balanced portfolio.
